Peritoneal CarcinomatosisNCT05300789
Metachonous Peritoneal Carcinomatosis Incidence After Curative Surgery for pT4 Colon Cancer Patients
An observational study of Peritoneal Carcinomatosis and Colon Cancer, run by Carlos Cerdán Santacruz at 1 site in Spain.
Trial summary
This is an observational retrospective cohort study to determine metachronous peritoneal carcinomatosis in a specific subgroup of colon cancer patients, those with a final pathologic exam corresponding to pT4 tumors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Peritoneal Carcinomatosis, Colon Cancer
- What is being tested?
- Follow-up
- How many people
- 1,152 participants
- Where
- 1 siteSpain
- Study dates
- 1 Mar 2021to 15 Jul 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult colon cancer patients operated on with curative intention, both scheduled and emergency surgery, with pathologic confirmation of pT4 tumors.
Who may be able to join
- Colon cancer above 15 cm from anal verge
- Curative intent surgery
- Pathologic confirmation of pT4 adenocarcinoma
- Pathologic diagnosis of colon cancer other than adenocarcinoma, such as GIST, leiomyosarcomas, neuroendocrine tumors, or other types even more unusual.
Who cannot join
- R2 cancer resection
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Peritoneal Recurrence Among pT4 Colon Cancer Tumors: Epidemiology, Oncologic Outcomes and Risk-stratification Model. Results From an Observational Retrospective Multicenter Long-term Follow-up Study
This is an observational retrospective cohort study to determine metachronous peritoneal carcinomatosis in a specific subgroup of colon cancer patients, those with a final pathologic exam corresponding to pT4 tumors.
Based on a sample size calculation of 1152 patients, a retrospective review of a three year period of every participant hospitals, 50 in total, of different characteristics, was stablished.
Demographic, clinical, operative, histologic and oncologic follow-up variables were recorded.
Read the detailed description
This is an observational retrospective cohort study to determine metachronous peritoneal carcinomatosis in a specific subgroup of colon cancer patients, those with a final pathologic exam corresponding to pT4 tumors.
A national multicenter retrospective cohort study is proposed. Given that the objectives of the study is to establish the prognostic oncologic impact of developing metachronous peritoneal carcinomatosis, it is intended to include patients who have completed three years of follow-up, therefore, the period of inclusion of patients to be analyzed is from 2015 to 2017.
Inclusion criteria:
- Patients operated on for colon cancer, considering those patients with neoplasia located from 15 cm from the anal margin in the proximal direction.
- Patients with histological confirmation of colon adenocarcinoma.
- Postoperative anatomical-pathological staging pT4a and pT4b.
- Patients operated both electively and urgently.
- Patients in whom a complete macroscopic resection of the primary tumor is achieved.
Exclusion criteria:
- Histological types other than adenocarcinoma, such as leiomyosarcomas, GIST, neuroendocrine tumors and other less frequent forms.
- Patients in whom the persistence of macroscopic oncological disease is described after the intervention on the primary tumor, considering it totally unresectable.
Definitions:
Definition of peritoneal carcinomatosis: presence of oncological disease at the peritoneal level, whether single or multifocal, and that is clearly recognizable and distinguishable from other forms of loco-regional recurrence of colon cancer such as anastomotic, mesenteric or lymph node recurrence and retroperitoneal form.
Definition of second look type surgery: it is considered all that programmed intervention carried out to rule out the presence of peritoneal carcinomatosis based on anatomo-pathological or clinical data related to the primary tumor and its debut form, but without the existence of clinical, analytical data or radiological during follow-up that allow it to be suspected.
Variables collected:
- Center code: each participating center will receive an exclusive code that will be the first variable in the database in order to identify the participation of each center in the study.
- Patient code: each patient included in each center will receive a consecutive numerical code to identify the participation of each center in the study.
- Demographic variables: sex, date of birth, body mass index (BMI).
- Patient comorbidity: the comorbidity of the collected patients will be shown exclusively with the anesthetic risk of the American Association of Anesthesiology (ASA Score).
- Primary neoplasm: diagnosis by presence and type of symptoms or diagnosis in the asymptomatic phase, location of the tumor and preoperative clinical staging based on extension studies.
- Operative data: date of the intervention, type of intervention (urgent vs. scheduled), approach, findings, type of resection performed, primary anastomosis or not, diverting or terminal stoma and postoperative complications at 30 days, especially those of infectious origin intra-abdominal. The rest of the complications that arise will be collected according to the Clavien-Dindo classification but will not be specified.
- Anatomical-pathological data: result of the cytological study if it has been carried out, histological type of the tumor, degree of differentiation, tumor staging according to the TNM classification and other histological prognostic criteria such as vascular, lymphatic and perineural infiltration.
- Adjuvant treatments: it will be collected if the patient underwent adjuvant treatment or not and if the proposed chemotherapy scheme could be carried out completely or was interrupted for any reason.
- Follow-up: performance of second look type surgery, findings during it, surgical technique performed, appearance or not of recurrence and the date of recurrence, type of recurrence (peritoneal carcinomatosis or distant metastasis), form of diagnosis of recurrence ( clinical, analytical, radiological or histological confirmation), salvage surgery for peritoneal carcinomatosis and, if so, rate of peritoneal carcinomatosis and technique used, performed in the same center or referral of the patient, performed by a unit specialized in surgery of peritoneal carcinomatosis or not, mortality and whether this was caused by the terminal evolution of the oncological process and the date of the last control (date of death or date of the last follow-up of the patient), with which the disease-free survival and the overall survival.
Calculation of the sample size. To carry out an adequate calculation of the sample size, the only multicenter prospective study at the national level of patients operated on for colon cancer, the ANACO study, has been used as a reference. In that study, with 52 participating centers, during a full year 3230 patients were registered who, after applying different exclusion criteria, remained in 2968, of which 550 patients were classified as T4 tumors after the histological study, that is, almost 20% of the tumors operated on in our environment.
Based on these figures, assuming a degree of participation similar to that obtained in the ANACO study, establishing an approximate figure of 1,500 pT4a/b colon tumors as the target population over the three years of study in our country. , an incidence of peritoneal carcinomatosis of approximately 15%, a confidence level of 95% and a precision of +/- 1 percentage units, a random sample of 1152 individuals is sufficient for the estimate to be made in this work.
Statistical method A descriptive analysis of demographic and clinical variables will be performed. Categorical variables will be presented as percentages and frequencies. The distribution of continuous variables will be evaluated using the Shapiro-Wilk statistic and they will be described as mean and standard deviation if they follow a normal distribution or as median and interquartile range (IQR) otherwise.
The association between the variables collected and the objective variables of the study will be made using Pearson's Chi-square test or Fisher's exact test, as appropriate, in the case of categorical variables and, for continuous variables, using Student's t-test for independent samples or Mann-Whitney U, respectively, depending on whether or not their distribution is adjusted to normal.
Project schedule and phases
- November - December 2020: Preparation and approval of the study protocol by the members of the Coloproctology Section of the Spanish Association of Surgeons.
- January - February 2020:
- Application for approval by the local ethics committees of the centers of the members of the Section involved in the project.
- Invitation to participate in the study by means of a formal letter to the department heads of the centers considered most representative and with the greatest volume in colon cancer surgery. For this purpose, the registry of participating centers in the previous ANACO registry has been used.
- Open invitation to all members of the Spanish Association of Surgeons through official communication by the Section of the start-up of the study.
- Preparation of the database in Excel format for later dissemination among the study participants.
- March - June 2020:
- Confirmation and commitment by the centers interested in participating in the study.
- Collection of data and sending of the files to those responsible for the project.
- July September:
- Condensation of the data from the different files into a single file.
- Statistical study and obtaining results.
- October - December 2021:
- Preparation of an original manuscript for submission and assessment for publication.
- Conditions
- Peritoneal Carcinomatosis, Colon Cancer
- Being tested
- Follow-up
- Keywords
- colon cancer, metachronous peritoneal carcinomatosis, epidemiology, risk factors
- Medical subject headings
- Peritoneal Neoplasms, Colonic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Follow-upOther
There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
| Study group | Role | What they receive |
|---|---|---|
| pT4 colon cancer patients after curative resection | Not described Receives: Other: Follow-up |
What is being measured
The primary outcome is the main question the study is designed to answer.
Metachronous peritoneal carcinomatosis
Number of patients diagnosed with peritoneal carcinomatosis during regular oncologic follow-up
Measured: A minimum of 3-years follow-up
Secondary outcomes (1)
Time to metachronous peritoneal carcinomatosis diagnosis
Time (months) from surgical treatment of primary tumor to diagnosis of peritoneal carcinomatosis during follow-up
Measured: A minimum of 3-years follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2022
- Study start1 Mar 2021
- Primary completion15 Jul 2021
- Study completion15 Jul 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peritoneal CarcinomatosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,152 participants (actual)
Sponsor and investigators
- Lead sponsor
- Carlos Cerdán Santacruz
- Sponsor type
- University, hospital or other
- Collaborators
- Spanish Association of Surgeons (AEC)
- Responsible party
- Sponsor-investigator, Carlos Cerdán Santacruz, Hospital San Carlos, Madrid
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05300789
- Sponsor's protocol ID
- 04/21-4398
- Status last verified
- Mar 2022
- First submitted
- 9 Mar 2022
- Last updated
- 29 Mar 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All information regarding this study will be shared under demand and with well documented and reasonable arguments.
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peritoneal Recurrence Among pT4 Colon Cancer Tumors: Epidemiology, Oncologic Outcomes and Risk-stratification Model. Results From an Observational Retrospective Multicenter Long-term Follow-up Study
- ClinicalTrials.gov ID
- NCT05300789
- Acronym / sponsor ID
- 04/21-4398
- Conditions
- Peritoneal Carcinomatosis, Colon Cancer
- Keywords
- colon cancer, metachronous peritoneal carcinomatosis, epidemiology, risk factors
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,152 participants (actual)
- Lead sponsor
- Carlos Cerdán SantacruzUniversity, hospital or other
- Collaborators
- Spanish Association of Surgeons (AEC)
- Study start
- 1 Mar 2021 (actual)
- Primary completion
- 15 Jul 2021 (actual)
- Study completion
- 15 Jul 2021 (actual)
- First posted
- 29 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observational retrospective cohort study to determine metachronous peritoneal carcinomatosis in a specific subgroup of colon cancer patients, those with a final pathologic exam corresponding to pT4 tumors.
Based on a sample size calculation of 1152 patients, a retrospective review of a three year period of every participant hospitals, 50 in total, of different characteristics, was stablished.
Demographic, clinical, operative, histologic and oncologic follow-up variables were recorded.
Detailed description
This is an observational retrospective cohort study to determine metachronous peritoneal carcinomatosis in a specific subgroup of colon cancer patients, those with a final pathologic exam corresponding to pT4 tumors.
A national multicenter retrospective cohort study is proposed. Given that the objectives of the study is to establish the prognostic oncologic impact of developing metachronous peritoneal carcinomatosis, it is intended to include patients who have completed three years of follow-up, therefore, the period of inclusion of patients to be analyzed is from 2015 to 2017.
Inclusion criteria:
- Patients operated on for colon cancer, considering those patients with neoplasia located from 15 cm from the anal margin in the proximal direction.
- Patients with histological confirmation of colon adenocarcinoma.
- Postoperative anatomical-pathological staging pT4a and pT4b.
- Patients operated both electively and urgently.
- Patients in whom a complete macroscopic resection of the primary tumor is achieved.
Exclusion criteria:
- Histological types other than adenocarcinoma, such as leiomyosarcomas, GIST, neuroendocrine tumors and other less frequent forms.
- Patients in whom the persistence of macroscopic oncological disease is described after the intervention on the primary tumor, considering it totally unresectable.
Definitions:
Definition of peritoneal carcinomatosis: presence of oncological disease at the peritoneal level, whether single or multifocal, and that is clearly recognizable and distinguishable from other forms of loco-regional recurrence of colon cancer such as anastomotic, mesenteric or lymph node recurrence and retroperitoneal form.
Definition of second look type surgery: it is considered all that programmed intervention carried out to rule out the presence of peritoneal carcinomatosis based on anatomo-pathological or clinical data related to the primary tumor and its debut form, but without the existence of clinical, analytical data or radiological during follow-up that allow it to be suspected.
Variables collected:
- Center code: each participating center will receive an exclusive code that will be the first variable in the database in order to identify the participation of each center in the study.
- Patient code: each patient included in each center will receive a consecutive numerical code to identify the participation of each center in the study.
- Demographic variables: sex, date of birth, body mass index (BMI).
- Patient comorbidity: the comorbidity of the collected patients will be shown exclusively with the anesthetic risk of the American Association of Anesthesiology (ASA Score).
- Primary neoplasm: diagnosis by presence and type of symptoms or diagnosis in the asymptomatic phase, location of the tumor and preoperative clinical staging based on extension studies.
- Operative data: date of the intervention, type of intervention (urgent vs. scheduled), approach, findings, type of resection performed, primary anastomosis or not, diverting or terminal stoma and postoperative complications at 30 days, especially those of infectious origin intra-abdominal. The rest of the complications that arise will be collected according to the Clavien-Dindo classification but will not be specified.
- Anatomical-pathological data: result of the cytological study if it has been carried out, histological type of the tumor, degree of differentiation, tumor staging according to the TNM classification and other histological prognostic criteria such as vascular, lymphatic and perineural infiltration.
- Adjuvant treatments: it will be collected if the patient underwent adjuvant treatment or not and if the proposed chemotherapy scheme could be carried out completely or was interrupted for any reason.
- Follow-up: performance of second look type surgery, findings during it, surgical technique performed, appearance or not of recurrence and the date of recurrence, type of recurrence (peritoneal carcinomatosis or distant metastasis), form of diagnosis of recurrence ( clinical, analytical, radiological or histological confirmation), salvage surgery for peritoneal carcinomatosis and, if so, rate of peritoneal carcinomatosis and technique used, performed in the same center or referral of the patient, performed by a unit specialized in surgery of peritoneal carcinomatosis or not, mortality and whether this was caused by the terminal evolution of the oncological process and the date of the last control (date of death or date of the last follow-up of the patient), with which the disease-free survival and the overall survival.
Calculation of the sample size. To carry out an adequate calculation of the sample size, the only multicenter prospective study at the national level of patients operated on for colon cancer, the ANACO study, has been used as a reference. In that study, with 52 participating centers, during a full year 3230 patients were registered who, after applying different exclusion criteria, remained in 2968, of which 550 patients were classified as T4 tumors after the histological study, that is, almost 20% of the tumors operated on in our environment.
Based on these figures, assuming a degree of participation similar to that obtained in the ANACO study, establishing an approximate figure of 1,500 pT4a/b colon tumors as the target population over the three years of study in our country. , an incidence of peritoneal carcinomatosis of approximately 15%, a confidence level of 95% and a precision of +/- 1 percentage units, a random sample of 1152 individuals is sufficient for the estimate to be made in this work.
Statistical method A descriptive analysis of demographic and clinical variables will be performed. Categorical variables will be presented as percentages and frequencies. The distribution of continuous variables will be evaluated using the Shapiro-Wilk statistic and they will be described as mean and standard deviation if they follow a normal distribution or as median and interquartile range (IQR) otherwise.
The association between the variables collected and the objective variables of the study will be made using Pearson's Chi-square test or Fisher's exact test, as appropriate, in the case of categorical variables and, for continuous variables, using Student's t-test for independent samples or Mann-Whitney U, respectively, depending on whether or not their distribution is adjusted to normal.
Project schedule and phases
- November - December 2020: Preparation and approval of the study protocol by the members of the Coloproctology Section of the Spanish Association of Surgeons.
- January - February 2020:
- Application for approval by the local ethics committees of the centers of the members of the Section involved in the project.
- Invitation to participate in the study by means of a formal letter to the department heads of the centers considered most representative and with the greatest volume in colon cancer surgery. For this purpose, the registry of participating centers in the previous ANACO registry has been used.
- Open invitation to all members of the Spanish Association of Surgeons through official communication by the Section of the start-up of the study.
- Preparation of the database in Excel format for later dissemination among the study participants.
- March - June 2020:
- Confirmation and commitment by the centers interested in participating in the study.
- Collection of data and sending of the files to those responsible for the project.
- July September:
- Condensation of the data from the different files into a single file.
- Statistical study and obtaining results.
- October - December 2021:
- Preparation of an original manuscript for submission and assessment for publication.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| pT4 colon cancer patients after curative resection | – | Other: Follow-up |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult colon cancer patients operated on with curative intention, both scheduled and emergency surgery, with pathologic confirmation of pT4 tumors.
Key inclusion criteria (4 listed)
- Colon cancer above 15 cm from anal verge
- Curative intent surgery
- Pathologic confirmation of pT4 adenocarcinoma
- Pathologic diagnosis of colon cancer other than adenocarcinoma, such as GIST, leiomyosarcomas, neuroendocrine tumors, or other types even more unusual.
Key exclusion criteria (1 listed)
- R2 cancer resection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Follow-upThere is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded. | Other | pT4 colon cancer patients after curative resection |
Primary outcome
Metachronous peritoneal carcinomatosis
Time frame: A minimum of 3-years follow-up
Number of patients diagnosed with peritoneal carcinomatosis during regular oncologic follow-up
1 secondary outcome
Time to metachronous peritoneal carcinomatosis diagnosis
Time frame: A minimum of 3-years follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2022.
- Individual participant dataSharing planned: Yes. All information regarding this study will be shared under demand and with well documented and reasonable arguments.
Related trials for Peritoneal Carcinomatosis
RecruitingPhase 1
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
RecruitingPhase 1
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 2
Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis
Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis
Active, not recruitingPhase 1
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Anal Carcinoma, Bladder Carcinoma
RecruitingPhase 1
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma
Mesothelin Positive, Mesothelin-Expressing Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Peritoneal Carcinomatosis and Colon Cancer, run by Carlos Cerdán Santacruz at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Metachronous peritoneal carcinomatosis (time frame: A minimum of 3-years follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2022.